Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

  • the C-TEAM study group and the Taiwan Liver Diseases Consortium

研究成果: 雜誌貢獻 › 文章 › 同行評審

196 引文 斯高帕斯（Scopus）

指紋

深入研究「Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients」主題。共同形成了獨特的指紋。

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science